Clinical analysis of 217 patients with gastrointestinal stromal tumor.
- Author:
Peng ZHANG
1
;
Wei-qiang ZHENG
;
Kai-xiong TAO
;
Xiao-ming SHUAI
;
Gao-xiong HAN
;
Guo-bin WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; diagnosis; surgery; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Young Adult
- From: Chinese Journal of Gastrointestinal Surgery 2012;15(3):251-254
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical characteristics, diagnosis, treatment and prognostic factors of gastrointestinal stromal tumor(GIST).
METHODSClinicopathological data of 217 GIST patients from January 2005 to September 2010 in Wuhan Union Hospital were analyzed retrospectively and the prognostic factors were evaluated.
RESULTSThere were 103 males and 114 females with a median age of 55 years old. Two hundred and thirteen patients underwent R0 resection and 4 R1 resection due to extensive invasion. Thirty-five patients underwent laparoscopic resection. Forty-eight patients received imatinib mesylate therapy after surgery. A total of 178 patients(82.0%) were followed up for 3 to 74 months. Sixteen patients(9.0%) developed recurrence or metastasis. Logistic regression analysis showed that tumor location (OR=2.547, 95% CI:1.466-4.424) and mitotic count(OR=6.556, 95% CI:2.974-14.449) were independent factors for post-operative recurrence or metastasis. Five patients survived with tumor, and 11 patients(6.2%) died of GIST including intestinal GIST(n=7) and extraintestinal GIST(n=4). Cox regression analysis showed that the mitotic count (RR=2.654, 95% CI:1.094-6.438) and post-operative recurrence or metastasis (RR=32.988, 95% CI:3.879-280.529) were independent prognostic factors.
CONCLUSIONSTumor location and mitotic count are independent risk factors for post-operative recurrence or metastasis in GIST. Mitotic count and post-operative recurrence or metastasis are independent indicators of poor prognosis. Surgical radical resection combined with targeted therapy can achieve satisfactory outcomes in patients with GIST.